<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00140218</url>
  </required_header>
  <id_info>
    <org_study_id>11736</org_study_id>
    <nct_id>NCT00140218</nct_id>
  </id_info>
  <brief_title>R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis</brief_title>
  <official_title>Futility Study of R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bennett, James P., Jr., M.D., Ph.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bennett, James P., Jr., M.D., Ph.D.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of this study is that treatment with R(+) pramipexole at 30 mg/day will alter
      the slope of decline in ALS functional rating scale over the course of 6 months. ALS patients
      at an early stage of disease will be observed for 3 months after enrollment and then treated
      with drug for 6 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a futility design Phase II study using ALS-FRSr as the primary variable to monitor
      progression of disease in patients with early ALS. The drug to be tested is R(+) pramipexole,
      an antioxidant that concentrates into brain and mitochondria. R(+)PPX will be administered at
      30 mg/day over 6 months, following a 3 month lead-in period without drug therapy. For
      purposes of this study, futility is defined as failure to decrease the slope of ALS-FRSr
      decline by less than 40%.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ALS-FRSr score taken each month for 3 months during lead-in and for 6 months during treatment</measure>
    <time_frame>-3 -2 -1 0 1 2 3 4 5 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>FVC taken each month</measure>
    <time_frame>-3 -2 -1 0 1 2 3 4 5 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hand dynamometry taken each month</measure>
    <time_frame>-3 -2 -1 0 1 2 3 4 5 6</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R(+) pramipexole dihydrochloride monohydrate</intervention_name>
    <description>10 mg tid oral</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  established diagnosis of ALS FVC&gt;60% of predicted not being ventilated no difficulty
             swallowing ambulatory (can use assistance devices)

        Exclusion Criteria:

          -  ALS duration &gt;3 years advanced ALS with survival predicted &lt;6 months dementia
             (MMSE&lt;22) prior exposure to R(+) pramipexole orthostatic hypotension &gt;30 mmHg history
             of psychosis or hallucinations abnormal baseline safety lab values
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence H Phillips, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>David Lacomis MD</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2005</study_first_submitted>
  <study_first_submitted_qc>August 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2005</study_first_posted>
  <last_update_submitted>January 5, 2008</last_update_submitted>
  <last_update_submitted_qc>January 5, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2008</last_update_posted>
  <responsible_party>
    <name_title>James P. Bennett Jr. M.D. Ph.D. Sponsor</name_title>
    <organization>University of Virginia</organization>
  </responsible_party>
  <keyword>amyotrophic lateral sclerosis</keyword>
  <keyword>pramipexole</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>neuroprotection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramipexole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

